Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual ...
Treatment responses to Xalkori were not affected by PD-L1 expression in patients with advanced non-small cell lung cancer and ROS1 rearrangements. Patients with advanced non-small cell lung cancer ...
FDA approved a PD-L1 companion test to identify patients with ovarian, fallopian tube or primary peritoneal cancer who may receive Keytruda. The U.S. Food and Drug Administration (FDA) has approved PD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results